


---

# Prediction of AF episodes in patients with lone atrial fibrillation

---

V Vassilikos MD, FACC, FESC  
Associate Professor in Cardiology  
Aristotle University of Thessaloniki


# Prevalence of AF predicted to more than double by 2050



# Leading circle- functional re-entry


## Reentry: Role of Refractory Period, Conduction and Wavelength Changes

**A**



Wavelength (WL) =  
refractory period x conduction velocity  
- minimal path length for reentry  
- size of functional reentry circuits



**B**





Normal atrial size  
Normal WL  
- reentry unstable  
- AF not sustained

Normal atrial size  
Short WL  
(↓RP, ↓CV)  
- AF sustained


# PAFib initiation






# Atrial musculature

*Nathan and Eliakim. Circulation 1966*




# Anatomy




## Bachmann's Bundle

- Delayed conduction
- Block
- Inhomogeneous anisotropic conduction




## Posterior interatrial connections

- Delayed conduction





Anisotropic conduction

IASeptum




Anisotropic re-entry

# Intra-atrial septal activation




**30 msec:** left anterior IAAS activation  
through Bachmann's bundle

**51 msec:** left anterior IAAS activation  
through foramen ovale




Left IAASeptum – left view. The double activation front. (Harrild et al, Circ Res 2000)

# Postero-inferior left atrium



The 3 activation fronts



\* Postero-inferior view - LA

(Harrild et al, Circ Res 2000).

---


# Non invasive methods


- P-wave duration
  - P-wave dispersion
  - P-wave SAECG
  - P-wave wavelet analysis
-

**normal**

**PAF**


**Adv IAA block**





## Posterior IAA connections

## Bachmann's bundle



- 
- Time-domain analysis
  - Frequency-domain analysis
  - Time-frequency domain analysis
-

## Prediction of atrial fibrillation in patients with cardiac dysfunctions<sup>†</sup>


P wave signal-averaged ECG and chemoreflexsensitivity in atrial fibrillation

Table 4 Univariate and multivariate predictors of atrial fibrillation

	Univariate			Multivariate		
	OR	95% CI	P-value	OR	95% CI	P-value
FPD $\geq$ 125 ms and RMS 20 $\leq$ 3.3 $\mu$ V	9.63	4.23-21.91	<0.0001	18.71	4.85-72.16	<0.0001
Ejection fraction $\leq$ 20%	2.43	1.14-5.18	0.022	6.60	1.42-30.62	0.02
Left atrial size $\geq$ 44 mm	3.72	1.68-8.23	0.001	1.90	0.55-6.63	0.32

FPD, filtered P wave duration; RMS 20, root mean square voltage of the last 20 ms of the P wave.

# Afib occurrence (FPD > 125ms and RMS $20 < 3.3\mu V$ )



# Prediction of atrial fibrillation in patients with cardiac dysfunctions<sup>†</sup>

## P wave signal-averaged ECG and chemoreflex sensitivity in atrial fibrillation

Table 2 Predictive values of the measurements of P-SAECG and echocardiography

	Specificity	Sensitivity	PPV	NPV	Accuracy
FPD $\geq$ 125 ms and RMS 20 $\leq$ 3.3 $\mu$ V	77	79	54	92	78
CHRS $\leq$ 3.0 ms/mmHg	57	54	30	78	56
Left atrial size $\geq$ 44 mm	74	46	38	80	67
Ejection fraction $\leq$ 20%	86	38	47	80	73

NPV, negative predictive value; PPV, positive predictive value.

- 
- Wavelet analysis is a spectro-temporal technique which can reveal dynamic changes within each frequency band during the duration of the cardiac cycle length
-

# Morlet transformation wavelet

$$W(u, a) = \frac{1}{\sqrt{a}} \int f(t) * \varphi\left(\frac{t-u}{a}\right) dt, \quad \varphi(t) = \frac{1}{\sqrt{2\pi\sigma}} e^{-j\omega t} e^{-t^2/2\sigma^2}$$


where  $\varphi(t)$  is the Morlet mother wavelet  
a: scale, u: time

---

# Short time Fourier analysis (STFT) vs Wavelet analysis

## Window used for the signal analysis

- Constant window for all frequencies
  - Inverse relation between time – frequency
  - Dynamic window (analyzed wavelet)
  - Time (window width-time)
  - Scale (frequency amplitude)
  - Best application for temporary signals which transform during time, i.e. ECG
-






Contents lists available at [ScienceDirect](#)

## International Journal of Cardiology

journal homepage: [www.elsevier.com/locate/ijcard](http://www.elsevier.com/locate/ijcard)



### Novel non-invasive P wave analysis for the prediction of paroxysmal atrial fibrillation recurrences in patients without structural heart disease A prospective pilot study

Vassilios Vassilikos<sup>a</sup>, George Dakos<sup>a</sup>, Yiannis S. Chatzizisis<sup>a,\*</sup>, Ioanna Chouvarda<sup>b</sup>, Charalambos Karvounis<sup>a</sup>, Charles Maynard<sup>c</sup>, Nicos Maglaveras<sup>b</sup>, Stylianos Paraskevaidis<sup>a</sup>, George Stavropoulos<sup>a</sup>, Charalambos I. Styliadis<sup>a</sup>, Sotirios Mochlas<sup>a</sup>, Ioannis Styliadis<sup>a</sup>

<sup>a</sup> 1st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece

<sup>b</sup> Medical Informatics Laboratory, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece

<sup>c</sup> Department of Health Services, University of Washington, Seattle, WA, United States

---

# Materials and methods

- ❖ Standard 12 lead ECG
  - ❖ Echocardiogram
  - ❖ P wave wavelet analysis with the Morlet wavelet during sinus rhythm
-

---

# Materials and methods

- ❖ Morlet wavelet analysis:

  - 3 channel digital recorder

  - Frank orthogonal leads X, Y, Z

  - Sampling frequency of 1000Hz

- ❖ The **vector magnitude** was calculated:

$$VM = \sqrt{X^2 + Y^2 + Z^2}$$


- ❖ Custom made software for wavelet signal decomposition
-

# Wavelet parameters



- ❖ *Mean energy (MN)* which corresponds to the area under the spectral curve during the P wave

$$Ea = \sum_{i=begin}^{end} W(i,a) * W(i,a)$$

- ❖ The *Maxima (MX)* corresponding at the global maximum energy of the spectral curve under the P wave
- ❖ MN and MX were calculated in three frequency bands (200-160Hz [1], 150-100Hz [2], 90-50Hz [3])



### P wave wavelet analysis



---

# Methods

- Group A (<5 AF episodes/year)
  - Group B (>5 AF episodes/year)
  - Group C (Normal controls)
-

# Echo parameters

Echocardiographic parameters of the study subjects at baseline.

	Group A (n = 33, <5 episodes/year)	Group B (n = 17, >5 episodes/year)	p	Groups A & B (n = 50)	Group C (n = 50, control)	p
Lald (cm)	4.98 ± 0.7	5.33 ± 0.3	0.055	5.09 ± 0.6	4.69 ± 0.6	<b>0.012</b>
Latd (cm)	2.91 ± 0.5	3.32 ± 0.7	0.026	3.04 ± 0.6	3.14 ± 0.5	0.510
Lals (cm)	4.24 ± 0.6	4.69 ± 0.5	<b>0.011</b>	4.39 ± 0.6	4.18 ± 0.6	0.170
Lats (cm)	2.36 ± 0.5	2.54 ± 0.6	0.193	2.39 ± 0.5	2.59 ± 0.5	0.130
LVDD (mm)	49.5 ± 4	49.3 ± 5	0.937	49.4 ± 4	46.5 ± 5	<b>0.019</b>
LVSD (mm)	28.5 ± 7	28.4 ± 10	0.207	28.4 ± 7	28.1 ± 7	0.380
EF (%)	66 ± 3	66 ± 3	0.656	66 ± 3	65 ± 5	0.160

Values are presented as mean ± SD. Lald: left atrial longitudinal diameter in end-diastole, Latd: left atrial transverse diameter in end-diastole, Lals: left atrial longitudinal diameter in end-systole, Lats: left atrial transverse diameter in end-systole, LVDD: left ventricular diastolic dimension, LVSD: left ventricular systolic dimension, EF: ejection fraction.

# P wave at baseline

P wave duration at baseline.

	Group A (n=33, <5 episodes/year)	Group B (n=17, >5 episodes/year)	p	Groups A & B (n=50)	Group C (n=50, control)	p
PdurX (msec)	70 ± 8	71 ± 18	0.801	70.4 ± 12	70.7 ± 12	0.870
PdurY (msec)	81.6 ± 13	88.1 ± 14	0.117	83.8 ± 14	80 ± 12	0.130
PdurZ (msec)	85.8 ± 13	87.7 ± 13	0.630	86.4 ± 13	71.5 ± 15	<b>&lt;0.001</b>
PdurVM (msec)	88.4 ± 14	91.2 ± 11	0.425	89.3 ± 13	81.8 ± 15	<b>0.008</b>

Pdur: P wave duration, X: X lead, Y: Y lead, Z: Z lead, VM: vector magnitude.

# Mean and Max P wave energy

Mean and maximum P wave energy values at baseline.


	Group A (n=33, <5 episodes/year)	Group B (n=17, >5 episodes/year)	p	Groups A & B (n=50)	Group C (n=50, control)	p
Mean1X	1.55 ± 1	2.07 ± 0.9	0.081	1.73 ± 0.9	2.16 ± 1.2	0.059
Mean2X	3.18 ± 1.9	4.31 ± 2.1	0.077	3.56 ± 2.1	4.68 ± 2.6	0.020
Mean3X	14.1 ± 7.3	17.7 ± 17.2	0.309	15.3 ± 11.6	24.2 ± 15.7	<b>0.002</b>
Max1X	8.96 ± 2.9	11.1 ± 2.5	<b>0.013</b>	9.7 ± 2.9	10.8 ± 3.2	0.090
Max2X	12.3 ± 3.3	14.5 ± 3.5	0.041	13.1 ± 3.5	15 ± 4.3	0.020
Max3X	22.5 ± 5.9	27.7 ± 6.9	<b>0.014</b>	24.3 ± 6.7	29.3 ± 9.5	<b>0.003</b>
Mean1Y	2.25 ± 1.3	2.59 ± 1.8	0.503	2.36 ± 1.5	2.35 ± 1.4	0.960
Mean2Y	4.86 ± 2.9	5.67 ± 4.2	0.481	5.14 ± 3.4	5.34 ± 3.3	0.760
Mean3Y	27.8 ± 15.1	23.2 ± 17.2	0.337	26.2 ± 15.8	30.9 ± 23.1	0.240
Max1Y	10.5 ± 3.3	10.8 ± 4	0.721	10.6 ± 3.5	10.7 ± 3	0.890
Max2Y	14.6 ± 4.8	15.2 ± 6.7	0.772	14.8 ± 5.5	15.2 ± 4.3	0.690
Max3Y	29.7 ± 9	26.2 ± 10.2	0.223	28.5 ± 9.5	31.6 ± 10.3	0.120
Mean1Z	3.02 ± 2.2	3.58 ± 1.8	0.376	3.2 ± 2.1	2.09 ± 1.1	<b>0.001</b>
Mean2Z	7.39 ± 6.5	7.82 ± 4.3	0.808	7.54 ± 5.8	4.84 ± 2.9	<b>0.005</b>
Mean3Z	35.1 ± 21.9	44.6 ± 27.3	0.224	38.3 ± 24.1	27.9 ± 15.9	<b>0.012</b>
Max1Z	12.1 ± 3.9	13.2 ± 3.4	0.310	12.5 ± 3.8	10.5 ± 3	<b>0.005</b>
Max2Z	17.5 ± 5.8	18.5 ± 5.2	0.545	17.8 ± 5.6	15.2 ± 4.8	<b>0.013</b>
Max3Z	34.5 ± 10.4	38.7 ± 11.5	0.203	36 ± 10.8	31.4 ± 9.9	0.031
Mean1VM	2.26 ± 0.5	2.73 ± 1.5	0.222	2.42 ± 0.9	2.11 ± 0.9	0.100
Mean2VM	4.4 ± 1.6	4.06 ± 2.1	0.532	4.29 ± 1.8	4.22 ± 1.9	0.090
Mean3VM	17.9 ± 6.9	16.9 ± 11.9	0.747	17.6 ± 8.8	19.8 ± 12.9	0.320
Max1VM	9.7 ± 1.4	10.7 ± 3.1	0.235	10 ± 2.1	9.88 ± 2.1	0.720
Max2VM	13.6 ± 2.8	14.9 ± 4.9	0.334	14 ± 3.7	13.5 ± 3.4	0.460
Max3VM	25.8 ± 5.9	26.8 ± 9.8	0.666	26.1 ± 7.4	26.1 ± 6.8	0.960

Mean1, 2 and 3: mean energy value in the 1st, 2nd and 3rd frequency band, respectively, Max 1, 2 and 3: maximum energy value in the 1st, 2nd and 3rd frequency band, respectively, X: X lead, Y: Y lead, Z: Z lead, VM: vector magnitude. Energies are expressed in  $\mu V^2$ .

# Wavelets in the 3 groups


<5/year

P wave wavelet analysis  
(Group A patient)




>5/year  
(time, msec)

P wave wavelet analysis  
(Group B patient)



P wave wavelet analysis  
(Group C subject)




Logistic regression analysis for patients any number of PAF recurrences per year (Groups A and B) vs. healthy controls without history of PAF (Group C).

		B	SE	p
Step 1	PdurZ	76.892	17.563	<0.001
	Constant	-6.073	1.409	<0.001
Step 2	Mean3X	-66.93	22.567	<b>0.003</b>
	PdurZ	84.114	18.775	<b>&lt;0.001</b>
	Constant	-5.361	1.460	<0.001

Mean3X: mean P wave energy at the 3rd frequency band in the X orthogonal lead,  
PdurZ: P wave duration in the Z lead.

(a)

PAF recurrences vs. no PAF




Logistic regression analysis for PAF patients with more than five recurrences per year (Group B) vs. patients with less than five recurrences per year (Group A).

		B	SE	p
Step 1	Max1X	293.710	126.888	0.021
	Constant	-3.675	1.342	0.006
Step 2	Lals	1.551	0.678	<b>0.022</b>
	Max1X	308.018	139.925	<b>0.028</b>
	Constant	-10.80	3.651	0.003

Max1X: maximum P wave energy at the 1st frequency band in the X orthogonal lead,  
Lals: left atrial longitudinal diameter in end-systole.


(b)

Many vs. fewer PAF  
recurrences





# Time-scale representations of the Morlet wavelet transform at Z axis

AF patient



Normal control





	Area	SE	p
PdurZ	0.820	0.045	<0.001
Max3Z	0.627	0.058	0.035

# Can P Wave Wavelet Analysis Predict Atrial Fibrillation After Coronary Artery Bypass Grafting?

VASSILIOS VASSILIKOS, GEORGE DAKOS, IOANNA CHOUVARDA,\*  
LABROS KARAGOUNIS,\*\* HARALAMBOS KARVOUNIS,  
NIKOLAOS MAGLAVERAS,\* SOTIRIOS MOCHLAS, PANAGIOTIS SPANOS,+  
and GEORGE LOURIDAS

From the First Cardiology Division, \*Laboratory of Medical Informatics, and †Cardiac Surgery Division, Aristotle University of Thessaloniki, Greece, and the \*\*Division of Cardiology, Department of Medicine, University of Utah, Salt Lake City, Utah

**VASSILIKOS V., ET AL.: Can P Wave Wavelet Analysis Predict Atrial Fibrillation After Coronary Artery Bypass Grafting?** *The purpose of this study was the evaluation of Morlet wavelet analysis of the P wave as a means of predicting the development of atrial fibrillation (AF) in patients who undergo coronary artery bypass grafting (CABG). The P wave was analyzed using the Morlet wavelet in 50 patients who underwent successful CABG. Group A consisted of 17 patients, 12 men and 5 women, of mean age  $66.9 \pm 5.9$  years, who developed AF postoperatively. Group B consisted of 33 patients, 29 men and 4 women, mean age  $62.4 \pm 7.8$  years, who remained arrhythmia-free. Using custom-designed software, P wave duration and wavelet parameters expressing the mean and maximum energy of the P wave were calculated from 3-channel digital recordings derived from orthogonal ECG leads (X, Y, and Z), and the vector magnitude (VM) was determined in each of 3 frequency bands (200–160 Hz, 150–100 Hz and 90–50 Hz). Univariate logistic-regression analysis identified a history of hypertension, the mean and maximum energies in all frequency bands along the Z axis, the mean and maximum energies (expressed by the VM) in the 200–160 Hz frequency band, and the mean energy in the 150–100 Hz frequency band along the Y axis as predictors for post-CABG AF. Multivariate analysis identified hypertension, ejection fraction, and the maximum energies in the 90–50 Hz frequency band along the Z and composite-vector axes as independent predictors. This multivariate model had a sensitivity of 91% and a specificity of 65%. We conclude that the Morlet wavelet analysis of the P wave is a very sensitive method of identifying patients who are likely to develop AF after CABG. The occurrence of post-CABG AF can be explained by a different activation pattern along the Z axis. (PACE 2003; 26[Pt. II]:305–309)*

# CABG patients

**Table I.**  
Patient Demographic and Clinical Data

	<b>Group A</b>	<b>Group B</b>	<b>p</b>
N	17	33	
Age (years $\pm$ SD)	66.9 $\pm$ 5.8	62.4 $\pm$ 7.8	0.059
Male sex	12	29	0.141
Previous MI	13	22	0.468
Hypertension	16	23	0.032
DM	4	12	0.350
Past AF	1	1	0.635
Beta-blocker	8	23	0.120
ACEI	8	16	0.924
Calcium antagonist	7	16	0.623
Digoxin	2	1	0.234
Diuretic	5	5	0.242
LA (mm $\pm$ SD)	41.5 $\pm$ 3.2	39 $\pm$ 6.1	0.306
LVDD (mm $\pm$ SD)	57.7 $\pm$ 6.9	57.8 $\pm$ 6.2	0.946
EF (% $\pm$ SD)	56 $\pm$ 12	49 $\pm$ 14	0.064
CBP time (min $\pm$ SD)	112 $\pm$ 68	82 $\pm$ 44	0.251
Clamp time (min $\pm$ SD)	65 $\pm$ 41	43 $\pm$ 28	0.181

MI = myocardial infarction, DM = diabetes mellitus, AF = atrial fibrillation, ACEI = angiotensin-converting enzyme inhibitor, LA = left atrium, LVDD = left ventricular diastolic dimension, EF = ejection fraction, CBP = cardiopulmonary bypass, SD = standard deviation.

# CABG patients

**Table II.**

Univariate Associates with the Risk of Developing Atrial Fibrillation

	<b>Group A</b>	<b>Group B</b>	<b>p</b>
MEAN2-Y	3.4781	5.5107	0.028
PZ	86.4510	78.4628	0.081
MEAN1-Z	1.7711	1.2446	0.038
MEAN2-Z	3.6416	2.2511	0.003
MEAN3-Z	18.9990	12.4711	0.001
MAX1-Z	9.5439	7.6656	0.002
MAX2-Z	12.9006	10.6525	0.003
MAX3-Z	26.8923	20.4865	0.000
MEAN1-VM	1.8837	1.4869	0.035
MAX1-VM	8.5511	7.6898	0.022
MAX2-VM	11.4283	10.4926	0.074
MAX3-VM	21.5240	19.2208	0.067
Age (years)	66.9	62.4	0.073
HTN	16 (94%)	23 (70%)	0.043
EF (%)	56	49	0.071

Variables with  $p = 0.1$  were included in the multivariate analysis. MEAN1 = mean energy in the 200-160 Hz frequency band, MEAN2 = mean energy in the 150-100 Hz frequency band, MEAN3 = mean energy in the 90-50 Hz frequency band, MAX1 = maximum energy in the 200-160 Hz frequency band, MAX2 = maximum energy in the 150-100 Hz frequency band, MAX3 = maximum energy in the 90-50 Hz frequency band, Y = Y axis, Z = Z axis, VM = vector magnitude, PZ = P-wave duration on the Z axis, HTN = hypertension, EF = ejection fraction.

# CABG patients

**Table III.**

Multivariate Model of the Most Significant Associates  
of Developing Postoperative Atrial Fibrillation

	<b>P</b>	<b>Coefficient</b>	<b>S.E.</b>
Model overall	<0.001		
MAX3-Z	0.006	0.434	0.159
MAX3-VM	0.066	0.293	0.160
HTN	0.014	4.232	1.721
EF	0.014	0.116	0.048



This model had a sensitivity of 91% and a specificity of 65%.  
MAX3-Z = maximum energy for the 90-50 Hz frequency band on  
the Z axis, MAX3-VM = maximum energy for the 90-50 Hz  
frequency band in vector magnitude, HTN = hypertension, EF =  
ejection fraction.

# Conclusions

	Energy P wave	Duration P wave	Sn	Sp	TPV	PPV	NPV
PAF with <5/year	↓ X	↑ PdurZ PdurZ-X	76	83	80	80	80
PAF with >5/year	↑ Z	↑ PdurZ PdurZ-X	84	75	82	91	60
PAF post CABG	↑ Z, VM	↑ PdurZ	90	87	87	74	96


# Postero-inferior

# Antero-superior



— AF patients  
— Normal controls

# Left septal activation



---


# Conclusions

- ❖ The P wave Morlet wavelet analysis in patients with PAF is indicative of a different activation along the postero-anterior direction.
  - ❖ Anisotropic conduction and the possible presence of dispersion of refractoriness at the anterior and posterior-lower right atrium may explain this activation pattern.
-

---

# agnowledgments


- G. Dakos MD
  - J. Chatzizisis MD
  - L. Mantziari MD
  - S. Mochlas MD
  - C. Karvounis MD
  - S. Theofilogianakos MD
  - N. Manglaveras PhD
  - I. Chouvarda PhD
-



PTF  $> 0.04$  mV . Ms has been found to be specific but less sensitive  
ECG marker of left atrial enlargement

# Prediction of atrial fibrillation in patients with cardiac dysfunctions<sup>†</sup>

P wave signal-averaged ECG and chemoreflexsensitivity in atrial fibrillation



## Logistic regression analysis Gr I vs Gr II

	<b>B</b>	<b>Std.Error</b>	<b>Wald</b>	<b>df</b>	<b>Sig.</b>
<b>P dur Z</b>	-74,721	21,415	12,174	1	<b>&lt;0,001</b>
<b>Mean2X</b>	319,695	132,678	5,806	1	<b>0,016</b>
<b>Mean1VM</b>	-1291,463	584,412	6,181	1	<b>0,027</b>
<b>Lalad</b>	-1,159	0,567	4,179	1	<b>0,041</b>

Group with <5 episodes/year (Ia)

Group with >5 episodes/year (Ib)

	<b>Group Ia (n=33)</b>	<b>Group Ib (n=17)</b>	<b>p</b>
<b>Lalad (cm)</b>	4,98 ± 0,7	5,43 ± 0,3	<b>0,05</b>
<b>Lasad(cm)</b>	2,91 ± 0,5	3,51 ± 0,69	<b>0,006</b>
<b>Lalas(cm)</b>	4,24 ± 0,6	4,85 ± 0,56	<b>0,005</b>
<b>Max3X (μV)</b>	22,5 ± 5,94	27,6 ± 8,35	<b>0,037</b>
<b>Mean2VM (μV)</b>	4,4 ± 1,63	3,05 ± 1,78	<b>0,03</b>

# Group with <5 episodes/year (Ia)

## Normal controls (II)

	<b>Group Ia (n=33)</b>	<b>Group II (n=50)</b>	<b>p</b>
<b>Lapl(cm)</b>	3,58±0,29	3,42±0,36	<b>0,046</b>
<b>Lvdd(cm)</b>	4,92±0,41	4,7±0,43	<b>0,037</b>
<b>P dur Z(msec)</b>	87,3±13	71,5±15	<b>&lt;0,001</b>
<b>P dur VM(msec)</b>	90,9±15	81,8±15	<b>0,005</b>
<b>P dur Z-X(msec)</b>	16,6±12	0,7±16	<b>&lt;0,001</b>
<b>Mean1X (μV)</b>	1,48±0,9	2,16±1,2	<b>0,003</b>
<b>Mean2X (μV)</b>	3,23±1,9	4,68±2,6	<b>0,003</b>
<b>Mean3X (μV)</b>	17,2±14,2	24,2±15,7	<b>0,008</b>
<b>Max1X (μV)</b>	8,77±2,9	10,8±3,2	<b>0,003</b>
<b>Max2X (μV)</b>	12,3±3,4	15±4,3	<b>0,002</b>
<b>Max3X (μV)</b>	23,6±7,8	29,3±9,5	<b>0,003</b>
<b>Mean2Z (μV)</b>	7,14±6,1	4,84±2,9	<b>0,046</b>
<b>Mean1VM(μV)</b>	2,44±0,9	2,11±0,8	<b>0,028</b>

---

	<b>R</b>	<b>R Square</b>	<b>Adj. R Square</b>	<b>Std.Error</b>	<b>R Square Change</b>	<b>F Change</b>	<b>df1</b>	<b>Sig. F Change</b>
<b>PdurZ-X</b>	0,482	0,233	0,224	0,44	0,233	26,688	1	<b>0,000</b>
<b>Max2X</b>	0,566	0,321	0,305	0,42	0,088	11,260	1	<b>0,001</b>


---

# Group with >5 episodes/year (Ib)


## Normal controls (II)

	<b>Ομάδα IB (n=17)</b>	<b>Ομάδα II (n=50)</b>	<b>p</b>
<b>Lalad(cm)</b>	5,35 ± 0,3	4,69 ± 0,62	<b>0,004</b>
<b>Lalas(cm)</b>	4,73 ± 0,57	4,18 ± 0,59	<b>0,018</b>
<b>P dur Z(msec)</b>	87,3 ± 14	71,5 ± 15	<b>0,003</b>
<b>P dur Z-X(msec)</b>	11,8 ± 13	0,7 ± 16	<b>0,049</b>
<b>Mean2Z (μV)</b>	7,11 ± 3,4	4,84 ± 2,9	<b>0,036</b>
<b>Mean3Z (μV)</b>	43 ± 21,7	27,9 ± 15,9	<b>0,013</b>
<b>Max1Z (μV)</b>	12,7 ± 3,7	10,5 ± 3	<b>0,044</b>
<b>Max3Z (μV)</b>	39,2 ± 10,7	31,4 ± 9,9	<b>0,028</b>

## Echo parameters



## Left parasternal



## Apical

